Systemic lupus erythematosus one disease or many?

被引:156
作者
Agmon-Levin, N. [1 ]
Mosca, M. [2 ]
Petri, M. [3 ]
Shoenfeld, Y. [1 ,4 ]
机构
[1] Chaim Sheba Med Ctr, Dept Med B, Zabludowicz Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
[2] Univ Pisa, Rheumatol Unit, I-56100 Pisa, Italy
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA
[4] Tel Aviv Univ, Incumbent Laura Schwarz Kip Chair Res Autoimmune, Tel Aviv, Israel
关键词
Systemic lupus erythematosus; Genetics; Environmental factors; Classification criteria; Personalized medicine; ANTIPHOSPHOLIPID SYNDROME; REVISED CRITERIA; FEATURES; CLASSIFICATION; ANTIBODIES; COMPLEMENT; DEFICIENCY; PROJECT; LESSONS;
D O I
10.1016/j.autrev.2011.10.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic lupus erythematosus (SLE) characterizes by a variety of clinical manifestations and the presence of a wide profile of autoantibodies. This clinical and serological heterogeneity raised the question: is SLE a single disease with varied phenotypes, or a similar phenotype shared by different diseases with diverse pathogenic mechanisms? Herein we debate the clinical, genetic, hormonal and serological differences typically observed in SLE on the one hand, and the numerous similarities between subtypes of this disease on the other. Leading to the conclusion that SLE may be considered not as a single disease but rather as a single syndrome, which defines by a set of signs, symptoms, or phenomena that occur together and suggest a particular abnormality. Additionally, the accumulated knowledge on gene expression pathways, autoantibodies clusters, hormonal and environmental factors associated with SLE may allow a better classification of this syndrome and updating of SLE criteria. This may further allow targeted biologics and other therapies as well as "personalized medicine" to begin. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:593 / 595
页数:3
相关论文
共 27 条
  • [1] Development of autoantibodies before the clinical onset of systemic lupus erythematosus
    Arbuckle, MR
    McClain, MT
    Rubertone, MV
    Scofield, RH
    Dennis, GJ
    James, JA
    Harley, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) : 1526 - 1533
  • [2] MOLECULAR ANALYSIS OF MAJOR HISTOCOMPATIBILITY COMPLEX ALLELES ASSOCIATED WITH THE LUPUS ANTICOAGULANT
    ARNETT, FC
    OLSEN, ML
    ANDERSON, KL
    REVEILLE, JD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (05) : 1490 - 1495
  • [3] Barr SG, 1999, ARTHRITIS RHEUM, V42, P2682, DOI 10.1002/1529-0131(199912)42:12<2682::AID-ANR26>3.0.CO
  • [4] 2-6
  • [5] Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the "Euro-Lupus Project"
    Cervera, R
    [J]. AUTOIMMUNITY REVIEWS, 2006, 5 (03) : 180 - 186
  • [6] Lessons from the "Euro-Phospholipid" project
    Cervera, Ricard
    [J]. AUTOIMMUNITY REVIEWS, 2008, 7 (03) : 174 - 178
  • [7] Criswell LA., 2011, RHEUMATOLOGIST FEB, P26
  • [8] Clusters of clinical and immunologic features in systemic lupus erythematosus:: Analysis of 600 patients from a single center
    Font, J
    Cervera, R
    Ramos-Casals, M
    García-Carrasco, M
    Sentís, J
    Herrero, C
    del Olmo, JA
    Darnell, A
    Ingelmo, M
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2004, 33 (04) : 217 - 230
  • [9] Clinical and genetic features of vascular Ehlers-Danlos syndrome
    Germain, DP
    [J]. ANNALS OF VASCULAR SURGERY, 2002, 16 (03) : 391 - 397
  • [10] INHERITED DEFICIENCY OF 2ND COMPONENT OF COMPLEMENT - RHEUMATIC DISEASE ASSOCIATIONS
    GLASS, D
    RAUM, D
    GIBSON, D
    STILLMAN, JS
    SCHUR, PH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1976, 58 (04) : 853 - 861